← All trials
NCT05772104
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Jun 1, 2025
- First posted
- Mar 16, 2023
- Last posted
- Mar 16, 2023
- Enrollment
- 560
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan Jishengtang Pharmaceutical Co., Ltd.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.